A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC

Inclusion Criteria:

• Has signs/symptoms of moderately to severely active UC for at least 3 months priorto Screening

• Has evidence of UC extending at least 15 cm from the anal verge

• Is bio-naïve or had an inadequate response, loss of response, or intolerance toother UC drugs

• Agrees to abide by the study guidelines and requirements

• Capable of giving signed informed consent

Exclusion Criteria:

• Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis,radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn'sdisease

• Has positive findings on a subjective neurological screening questionnaire

• Has a concurrent, clinically significant, serious, unstable comorbidity

• Primary non-responder to vedolizumab or other integrin inhibitors

• Participation in any other interventional study or received any investigationaltherapy within 30 days

• Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with asimilar mechanism to MORF-057

• Unable to attend study visits or comply with study procedures